CN102666525B - 氟取代的2-芳基-3,5-二氰基-4-吲唑基-6-甲基-1,4-二氢吡啶和其用途 - Google Patents

氟取代的2-芳基-3,5-二氰基-4-吲唑基-6-甲基-1,4-二氢吡啶和其用途 Download PDF

Info

Publication number
CN102666525B
CN102666525B CN201080050319.5A CN201080050319A CN102666525B CN 102666525 B CN102666525 B CN 102666525B CN 201080050319 A CN201080050319 A CN 201080050319A CN 102666525 B CN102666525 B CN 102666525B
Authority
CN
China
Prior art keywords
formula
compound
cancer
hydrogen
fluorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080050319.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102666525A (zh
Inventor
A.瓦卡洛波洛斯
M.米歇尔斯
K.齐默曼
N.托伊施
M.洛贝尔
K.恩格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN102666525A publication Critical patent/CN102666525A/zh
Application granted granted Critical
Publication of CN102666525B publication Critical patent/CN102666525B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080050319.5A 2009-11-11 2010-11-08 氟取代的2-芳基-3,5-二氰基-4-吲唑基-6-甲基-1,4-二氢吡啶和其用途 Expired - Fee Related CN102666525B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09175642 2009-11-11
EP09175642.9 2009-11-11
PCT/EP2010/066983 WO2011069761A1 (en) 2009-11-11 2010-11-08 Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof

Publications (2)

Publication Number Publication Date
CN102666525A CN102666525A (zh) 2012-09-12
CN102666525B true CN102666525B (zh) 2015-01-28

Family

ID=43629143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080050319.5A Expired - Fee Related CN102666525B (zh) 2009-11-11 2010-11-08 氟取代的2-芳基-3,5-二氰基-4-吲唑基-6-甲基-1,4-二氢吡啶和其用途

Country Status (7)

Country Link
US (1) US9018234B2 (enExample)
EP (1) EP2499124B1 (enExample)
JP (1) JP5753182B2 (enExample)
CN (1) CN102666525B (enExample)
CA (1) CA2777907C (enExample)
ES (1) ES2549132T3 (enExample)
WO (1) WO2011069761A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071451A1 (en) * 2006-12-14 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Dihydropyridine derivatives useful as protein kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635977A (en) 1969-11-03 1972-01-18 American Cyanamid Co Certain 6-trifluoromethylcytosines and thiocytosines their synthesis and their use in the synthesis of uracisls and thiouracil
JP2007526324A (ja) 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性のある阻害剤
BRPI0519031A2 (pt) 2004-12-13 2008-12-23 Irm Llc compostos e composiÇÕes como moduladores de atividades de receptores esteroidais e de canal de cÁlcio
CA2603676A1 (en) 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071451A1 (en) * 2006-12-14 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Dihydropyridine derivatives useful as protein kinase inhibitors

Also Published As

Publication number Publication date
JP2013510814A (ja) 2013-03-28
CN102666525A (zh) 2012-09-12
JP5753182B2 (ja) 2015-07-22
EP2499124A1 (en) 2012-09-19
US9018234B2 (en) 2015-04-28
CA2777907A1 (en) 2011-06-16
ES2549132T3 (es) 2015-10-23
EP2499124B1 (en) 2015-08-19
CA2777907C (en) 2017-08-29
US20130005773A1 (en) 2013-01-03
HK1177452A1 (en) 2013-08-23
WO2011069761A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
CN102573838B (zh) 氟取代的3,5-二氰基-4-(1h-吲唑-5-基)-2,6-二甲基-1,4-二氢吡啶衍生物和其使用方法
CN102574834B (zh) 氟化的2,6-二烷基-3,5-二氰基-4-(1h-吲唑-5-基)-1,4-二氢吡啶及其使用方法
CN102666525B (zh) 氟取代的2-芳基-3,5-二氰基-4-吲唑基-6-甲基-1,4-二氢吡啶和其用途
EP2501700B1 (en) Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof
CN102639537B (zh) 吲唑基取代的二氢异*唑并吡啶及其使用方法
HK1177452B (en) Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof
HK1172904B (en) Fluorinated 2,6-dialkyl-3,5-dicyano-4-(1h-indazol-5-yl)-1,4-dihydropyridines and methods of use thereof
HK1172904A (en) Fluorinated 2,6-dialkyl-3,5-dicyano-4-(1h-indazol-5-yl)-1,4-dihydropyridines and methods of use thereof
HK1172835B (en) Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG

Effective date: 20130327

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130327

Address after: German Monheim

Applicant after: Bayer Pharma Aktiengesellschaft

Address before: Berlin

Applicant before: Bayer Pharmaceuticals AG

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1177452

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1177452

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150128

Termination date: 20181108